Author:
Ren Hong-can,Sai Yang,Chen Tao,Zhang Chun,Tang Lily,Yang Cheng-guang
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41–57. https://doi.org/10.2165/00003088-200038010-00003.
2. Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O’Mara E, et al. Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. J Clin Pharmacol. 2016;56(2):143–51. https://doi.org/10.1002/jcph.562.
3. FDA. In vitro metabolism- and transporter-mediated drug–drug interaction studies guidance for industry. 2020. Available from: https://www.fda.gov/media/134582/download. Accessed 29 Aug 2021.
4. Ogasawara K, Xu C, Kanamaluru V, Palmisano M, Krishna G. Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. Cancer Chemother Pharmacol. 2020;85(5):899–906. https://doi.org/10.1007/s00280-020-04067-3.
5. FDA. New drug application, NOURIANZ, clinical pharmacology and biopharmaceutics reviews. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000ClinPharmR.pdf. Accessed 15 Sep 2021.